Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

Ib Clinical Trial of ANA598. Anadys has completed preparations required to initiate a Phase Ib clinical trial of ANA598, an investigational oral non-nucleoside polymerase inhibitor for the treatment of hepatitis C virus (HCV) infection, and expects to initiate patient dosing shortly. ANA598 will be administered to naive genotype 1a and 1b patients at 200 mg bid (twice-a-day), 400 mg bid or 800 mg bid over a period of three days. Anadys expects to have viral load data from this study in the first quarter of 2009. Based on the data from the first three cohorts, Anadys may elect to explore once daily dosing and/or other dose levels of ANA598.

-- Conclusion of Healthy Volunteer Study in Phase I Clinical Trial of ANA598. In September, Anadys announced preliminary results of the Phase I clinical trial of ANA598 in healthy volunteers and finalization of the protocol for a Phase Ib trial of ANA598 in HCV infected patients. ANA598 was well tolerated at all doses tested, and all doses achieved plasma drug concentrations predicted to display substantial antiviral activity based on preclinical data. Safety and PK data from all dose levels in the Phase I clinical trial of ANA598 will be presented in a late-breaker poster session on November 3 at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), to be held in San Francisco, California. Further preclinical data on ANA598 will be presented at AASLD in two additional poster presentations on November 4.

-- Initiation of Long-Term Chronic Toxicology Studies of ANA598. In September, Anadys initiated long-term chronic toxicology studies of ANA598. If ANA598 is successful in early stage clinical trials, it is anticipated that the acceleration of these and other non-clinical activities into 2008 will enable a more rapid and continuous development path into Phase II studies during 2009.

-- Phase I Clinical Trial of ANA773 in HCV. In July, Anadys announced that it was resuming
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Dallas, Texas (PRWEB) October 30, 2014 ... China Naltrexone HCL Industryā€¯ is a professional and ... The report provides basic Naltrexone HCL information, including ... as well as industry overview. This research covers ... as well as global industry analysis covering macroeconomic ...
(Date:10/30/2014)... Rancho BioSciences , the scientific ... curated public data source TCGA for several ... data is now available for other oncology groups. ... internal data sources for their Pharma, Government and academic ... data that becomes more easily accessible. Rancho advises ...
(Date:10/30/2014)... 2014 Whitehouse Laboratories has formally announced ... Testing and Package Test Capacity. Responding to growing demands ... dramatic increase in environmental chamber storage space that will ... aging samples to be securely held on site at ... expenditure has already taken place with the recent completion ...
(Date:10/30/2014)... Oct. 30, 2014 Isis Pharmaceuticals, Inc. (NASDAQ: ... that management will present a company overview at the Nomura ... ET in Boston, MA. ... the "Investors & Media" section of the Company,s website, ... website within 48 hours and will be archived for a ...
Breaking Biology Technology:Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 2Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 3Rancho BioSciences Manually Curated TCGA Data Sets Available 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2
... N.J., June 26 Barr Pharmaceuticals,Inc. (NYSE: ... for Delaware has,ruled in favor of its subsidiary, ... listed by Boehringer Ingelheim Pharmaceuticals, Inc. in,connection with ... 1mg & 1.5mg., In his ruling, District ...
... Strive to Measure ROI, Balance Business Benefits with ... Environmental Responsibility, FALLS ... supply chains are most constrained by the,inability to justify cost of ... conducted by CSC (NYSE: CSC ), Manhattan,Associates Inc. (Nasdaq: ...
... -, NUTLEY, N.J., June 26 Roche announced ... allow U.S. businesses,to maintain access to their own stockpile ... upfront investment and more adaptability,to deal with unknown factors ... businesses pay a nominal annual fee to "reserve",their own ...
Cached Biology Technology:Barr Announces Favorable Ruling in Mirapex(R) Patent Challenge 2Barr Announces Favorable Ruling in Mirapex(R) Patent Challenge 3Barr Announces Favorable Ruling in Mirapex(R) Patent Challenge 4Study Reveals Greatest Barrier to Green Supply Chain Initiatives 2Study Reveals Greatest Barrier to Green Supply Chain Initiatives 3Roche Introduces Program to Facilitate Corporate Pandemic Stockpiling of Tamiflu(R) 2Roche Introduces Program to Facilitate Corporate Pandemic Stockpiling of Tamiflu(R) 3Roche Introduces Program to Facilitate Corporate Pandemic Stockpiling of Tamiflu(R) 4Roche Introduces Program to Facilitate Corporate Pandemic Stockpiling of Tamiflu(R) 5
(Date:10/30/2014)... bioengineering professor has received a $1.04 million grant ... cartilage tissue and reduce osteoarthritis using a patient,s ... microscaffolding made of biodegradable polymers., Liping Tang, a ... department, said the research is primarily focused on ... battlefield., "We,ve found that if we inject microscaffolding ...
(Date:10/30/2014)... Rochelle, NY, October 30, 2014—Oligonucleotide-based therapeutics present unique ... to cause reproductive and developmental harm. New consensus ... the combined chemical and biological characteristics of these ... Therapeutics , a peer-reviewed journal from Mary ... available free on the Nucleic Acid Therapeutics ...
(Date:10/30/2014)... New York | Heidelberg, 30 October 2014 Biological ... a better understanding of adsorption of solution ions ... biological cells. Now, a new study provides a ... and surrounding solution ions. Joanna Kotyńska and Zbigniew ... the authors of a study describing these findings, ...
Breaking Biology News(10 mins):UTA researcher uses microscaffolding injections to mend cartilage, prevent osteoarthritis 2New guidelines for reproductive & developmental toxicity testing of oligonucleotide drugs 2Ion adsorption matter in biology 2
... launch of the International Giant Panda Genome Project. This announcement ... on January 2122, 2008, in Shenzhen, China. Dr. Hongmei Zhu, ... project is to finish the sequencing and assembling of the ... is a much loved animal all over the world and ...
... Calif., March 4 Atmel(R),Corporation (Nasdaq: ... PTEC ),announced today the integration of ... and SecureCore Pre-boot Authentication,(PBA) products., This ... industry leaders,provides for significantly stronger multifactor authentication ...
... the billions from Iceland,s Lake Myvatn are a force ... to breathe without inhaling the bugs, which hatch and ... short adult life, their carcasses blanket the lake, and ... surrounding landscape that the enhanced productivity can be measured ...
Cached Biology News:Giant panda genome to be sequenced 2Giant panda genome to be sequenced 3Atmel and Phoenix Technologies Collaborate to Create Next-generation Security Solutions for PCs 2Atmel and Phoenix Technologies Collaborate to Create Next-generation Security Solutions for PCs 3Lowly Icelandic midges reveal ecosystem's tipping points 2Lowly Icelandic midges reveal ecosystem's tipping points 3
... low temperature freezers offer a superior ... of biological samples with high capacities. ... inner doors ensure excellent warming protection ... ,Application oriented accessories simplify tracking of ...
...
Verotoxin IIbeta (457)...
... Universal Vacuum System UVS400 is a multi-tasking ... UVS400 combines a refrigerated vapor trap and ... single integrated unit. The easy-to-use, wide-mouth glass ... into single jar for easy disposal. The ...
Biology Products: